HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Partnered Content
Report Store
UsernamePublicRestriction
Tags:
Health OTC Drugs Prescription To Otc Switch

German Switch Decisions Should Be Informed By Science Not Ideology

  • News

Executive Summary

Science, not politics, should inform decisions about potential prescription-to-OTC switches, urges German federal pharmacy association, ABDA. 

You may also be interested in...



Stada Blasts German Sleep Aid Reverse Switch

Stada criticizes German switch committee's recommendation to restrict access to first generation antihistamines with a sedative effect for over-65s. 

Novartis Wins Landmark Case Against German Government Over Desloratadine Switch

Generics giant Novartis through its Hexal subsidiary has won an important case against the German Ministry of Health over a delayed prescription-to-OTC switch of desloratadine, which shows European Union Member States have got the authority to switch at a national level centrally authorized drugs. 

German Industry Wants To Simplify 'Complicated' Switch Process

The German Medicines Manufacturers´ Association

Table

View full table

Related Content

HBW Insight

Topics

Tags:
Health OTC Drugs Prescription To Otc Switch
UsernamePublicRestriction

Register

RS150157

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By